PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel ...

The study revealed that younger patients (16-24 years) with moderate-to-severe psoriasis were more likely to discontinue TNF ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 41 tables and 85 figures, this 159-page report ?Asia Pacific Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Women aged 18 to 45 years with IBD were invited to complete a survey regarding knowledge, attitude, and beliefs about contraception.

In conclusion, despite the potential that bacterial metabolites have as immunomodulators and for the treatment of immune-related illnesses, several obstacles and restrictions prevent their broad ...

Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou ...

immunomodulators, and/or biologics. Patients were randomly assigned to placebo or Omvoh; those in the placebo group who did not achieve clinical response at 12 weeks were switched to Omvoh treatment.

The approval is based on results of the phase 3 VIVID-1 study in adults with moderately to severely active Crohn disease with inadequate response, loss of response, or intolerance to corticosteroids, ...